Peter Rugbjerg

Part of McKinsey & Co., Inc., Mckinsey & Co. Denmark P/S is a Danish company that provides business and other management consultancy services. The company is based in Copenhagen, Denmark.

Part of Bain & Co., Inc., Bain & Co. Denmark Aps is a Danish company that champions bold ideas and teamwork to achieve extraordinary results. The company is based in Copenhagen, Denmark. The company align costs with strategy and focuses on growth to help companies create sustained value for customers and stakeholders in a tumultuous time. The company's annual report highlights the central role technology plays in the economy across all sectors and provides growth strategies to thrive in a challenging market.

Novo Nordisk Fonden provides basis for the commercial and research activities conducted by the companies. It also supports scientific and humanitarian purposes activities. It awards grants for research within biomedicine, biotechnology, general practice and family medicine, nursing, and art history at public research institutions. It bridges gap between the discoveries made by researchers in biomedicine and biotechnology and their commercial application. The company was founded by August Krogh, Marie Krogh, Harald Pedersen, Hans Christian Hagedorn, August Kongsted and Thorvald Pedersen in 1922 and is headquartered in Hellerup, Denmark.

Novozymes BioloAg A/S provides research and development for biotechnology products and processes. It participates in The BioAg Alliance to commercialize BioAg assets and competencies within microbial research, development, and production. The company was founded on October 22, 2007 and is headquartered in Bagsvaerd, Denmark.

Protera SAS manufactures protein-based ingredients to address critical challenges in food, agriculture, the environment, and human health. Its products include Guard, Sense, antioxidant proteins, and foaming and emulsifying proteins. The company was founded by Leonardo Álvarez and Francia Navarrete and is headquartered in Neuilly-sur-Seine, France.

Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers.

Novozymes Biopharma DK A/S engages in the wholesale of pharmaceuticals and medical article. The firm operates and invests in research, development, production, and trade in biological solutions, including pharmaceuticals, and biotechnology products and processes.The company was founded on May 29, 2006 and is headquartered in Bagsvaerd, Denmark.

Albumedix A/S is a Danish biotechnology company. The private company is based in Copenhagen, Denmark.

Chr. Hansen A/S engages in bioscience research that develops natural solutions for the food, nutritional, pharmaceutical and agricultural industries. It also develops and produces cultures, enzymes, probiotics and natural colors for a rich variety of foods, confectionery, beverages, dietary supplements and even animal feed. The company was founded by Christian D. A Hansen in 1874 and is headquartered in Horsholm, Denmark.